LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Mutations in leucine-rich repeat kinase (LRRK2) are a leading genetic cause of Parkinson's disease (PD).
• Elevated LRRK2 kinase activity is associated with common PD-linked mutations.
• Developing accurate preclinical models for PD is crucial for therapeutic development.

Purpose of the Study:

• To investigate the role of LRRK2 in modulating alpha-synuclein pathology and neurodegeneration in primary neuron cultures.
• To evaluate the efficacy of LRRK2 inhibitors in reducing alpha-synuclein aggregation and pathology in PD models.

Main Methods:

• Utilized primary neuron cultures, including hippocampal and midbrain dopaminergic neurons.
• Employed biochemistry and immunocytochemistry to assess alpha-synuclein aggregation and neurodegeneration.
• Tested the effects of familial mutant G2019S LRRK2 expression and three LRRK2 inhibitors.

Main Results:

• Expression of mutant G2019S LRRK2 did not significantly increase alpha-synuclein pathology or neurodegeneration.
• Robust inhibition of LRRK2 activity failed to reduce alpha-synuclein pathology in wildtype neurons.
• LRRK2 inhibition showed no effect on pathology seeded by human brain-derived alpha-synuclein.

Conclusions:

• LRRK2 activity has minimal impact on alpha-synuclein pathology in primary neuron models.
• Current LRRK2 inhibitors may not be effective in addressing alpha-synuclein pathology in PD.
• More complex preclinical models are likely required to assess LRRK2 inhibitor efficacy for PD treatment.